Skip to main content
Premium Trial:

Request an Annual Quote

HistoRx Extends Eli Lilly Deal for Biomarker Analysis Technology

NEW YORK (GenomeWeb News) – HistoRx said today that it has signed a three-year agreement to supply its biomarker analysis technology to drugmaker Eli Lilly and Company.

The company said it has extended and expanded a 2005 agreement to make its Aqua technology available to Lilly for use in its pharmaceutical development programs.

Under the agreement, HistoRx will give Lilly’s researchers access to the biomarker analysis technology and it will develop customized immunohistochemical assays for use in Lilly’s drug programs. HistoRx also gains the option to commercialize the assays and reagents that are developed over the course of the partnership for use as predictive diagnostics.

Financial terms of the agreement were not released.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.